Leukemia

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

Further research is necessary to determine whether regular DNA sequence testing for residual disease variants in patients with acute myeloid leukemia can improve outcomes.

Adult patients with chronic lymphocytic leukemia in the European Union can now receive treatment with acalabrutinib tablets.

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.

Data from the European phase 1 MB-105 trial indicate that the safety profile of annamycin in geriatric advance acute myeloid leukemia are consistent with previously reported findings.

An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Catherine Coombs explains the challenges of treating 17p deletions and Richter’s syndrome in patients with CLL and discusses the role of venetoclax in the treatment of these patients.

Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.

CAR T-cell therapy brexucabtagene autoleucel appears to produce an overall survival benefit among patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant.

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Catherine Coombs, MD, and Alexey Danilov, MD, PhD, discuss data on the investigational non-covalent BTK inhibitor pirtobrutinib for the treatment of CLL.

Investigators say that a phase 1/2 trial evaluating MGTA-117 in 2 hematologic malignancies has been paused following a serious adverse effect that may be related to the agent.

The panel explains the factors they consider when deciding on a BTK inhibitor for the treatment of patients with CLL.

Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.

Eleanor Mayfield, ELS, discusses FLT3-ITD minimal residual disease in acute myeloid leukemia.

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.

Patients with chronic lymphocytic leukemia and small lymphocytic leukemia can now receive treatment with zanubrutinib following its approval by the FDA.

Moxetumomab pasudotox-tdfk, approved as a treatment for relapsed/refractory hairy cell leukemia in 2018, will be withdrawn from the United States market in July 2023.

The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.

The Japanese approval of acalabrutinib for the treatment of patients with treatment-naïve chronic lymphocytic leukemia was supported by data from the phase 3 ELEVATE-TN trial.

Data presented at this year’s American Society of Hematology Annual Meeting spotlight promising novel treatment options for acute myeloid leukemia, according to an expert from The University of Texas MD Anderson Cancer Center.

Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.